Analysts Conflicted on These Healthcare Names: Viatris (VTRS) and Green Thumb Industries (OtherGTBIF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS – Research Report) and Green Thumb Industries (GTBIF – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Viatris (VTRS)
In a report released yesterday, Chris Schott from J.P. Morgan maintained a Hold rating on Viatris, with a price target of $17.00. The company’s shares closed last Friday at $14.93.
According to TipRanks.com, Schott is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Viatris with a $15.29 average price target, representing a 0.9% upside. In a report released yesterday, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $15.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Green Thumb Industries (GTBIF)
In a report issued on February 26, Aaron Grey from Alliance Global Partners maintained a Buy rating on Green Thumb Industries, with a price target of C$21.00. The company’s shares closed last Friday at $6.58, close to its 52-week low of $5.37.
According to TipRanks.com, Grey is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Green Thumb Industries with a $15.78 average price target, representing a 133.8% upside. In a report issued on February 26, Roth MKM also maintained a Buy rating on the stock with a $20.00 price target.
